Zoetis told investors that Librela was “the best launch ever in animal health.” Then the company’s first-quarter 2026 results came out, and the stock fell $23.91 on May 7, a drop of 21.5%, to close at $87.31.
That slide is at the center of a securities fraud class action. Investors have until July 27, 2026 to seek appointment as lead plaintiff in City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401, pending in federal court in the Southern District of New York. It charges violations of the Securities Exchange Act of 1934 and covers purchases of Zoetis securities from January 14, 2025 to May 6, 2026.
The complaint alleges that the company and its executives made materially false statements about operations, growth prospects and competitive threats, and that the shares traded at artificially inflated prices as a result.
Three products, three problems
Librela, a pain treatment for dogs, was losing prescription growth, the suit says, after FDA safety warnings about serious neurological complications, including seizures and death. Simparica Trio, which protects against fleas, ticks and heartworm, was ceding significant market share to a lower-priced rival with broader indicated use. The complaint names the rival as Elanco’s Credelio Quattro, which covered tapeworms where Trio did not. The dermatology drugs Apoquel and Cytopoint were losing share to Elanco’s Zenrelia, marketed as comparable or better at a lower price.
The suit contrasts that with what management said during the class period. Executives projected that the dermatology market would reach $2.5 billion by 2028, growing at 11% a year. They called Simparica Trio “the trusted first choice for veterinarians and pet owners alike.” By the first quarter of 2026, the complaint alleges, every pillar of that story had cracked.
It quotes management admitting “declining patient volume in the clinic” and conceding that “price has played a larger role in the decision process.”
The quarter
Zoetis reported net income of $601 million, flat from a year earlier. It cut its 2026 profit guidance to $6.85 to $7 a share from $7.00 to $7.10. Chief executive Kristin Peck said the quarter “unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand.”
The Companion Animal segment generates about 70% of Zoetis revenue. The company trades on the NYSE as ZTS.
Several law firms, including the Schall Law Firm, Kessler Topaz, Rosen, Levi & Korsinsky and Pomerantz, have urged affected investors to come forward. No action is needed to stay in the class. Only those who want to lead it must file by July 27.
